In our debut episode of IC Fireside Chats Omar Ali (Head of Payers, Verpora) and Adam Buckler (VP Innovative Contracting, Verpora) explore one of the most influential value-based agreements in oncology—the Velcade (Bortezomib) contract in the UK.

This case study highlights how a manufacturer navigated pricing negotiations, payer requirements, and access challenges to secure a broad market entry for a breakthrough multiple myeloma therapy.

The discussion examines how an innovative risk-sharing agreement allowed Velcade to overcome a payer impasse, balancing clinical uncertainty with financial guarantees. By offering a performance-based contract—where reimbursement was contingent on treatment success—this agreement reshaped oncology market access strategies and set a precedent for future value-based contracting models.

Watch Next